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Multiple sclerosis (MS) is a chronic, inflammatory, neurodegenerative demyelinating disease of the central nervous system 
(CNS). Inflammation is increased by high-energy Western-style diets, typically high in salt, animal fat, red meat, sugar-sweetened 
drinks and fried food, and low in fibre, as well as lack of physical exercise. An anti-inflammatory dietary regimen, with or without 
administration of dietary supplements, supporting the general trend towards an amelioration of inflammatory status, should be 
considered.
Understanding the role of gut microbiota in health and disease can lay the foundation to treat chronic diseases by modifying 
the composition of gut microbiota through lifestyle choices, including dietary habits and possibly probiotic supplementation.
Evidence from experimental, epidemiologic and clinical studies supports the potential association between poor vitamin D 
status and the risk of developing MS, as well as an adverse disease course. Correcting vitamin D status seems plausible in patients 
with MS.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, neurodegen-
erative demyelinating disease of the central nervous system 
(CNS).1–4 Its onset is more common in young adults and the dis-
ease has a female predominance.4 While the aetiology of MS is 
not completely understood, it seems to be a multifactorial entity 
that is influenced by both genetic and environmental modifica-
tions.1–5 Over the last 20 years evidence has emerged suggesting 
that distinct immunological pathways drive the progression and 
relapses of the disease. Thus, immunomodulatory drugs are 
used in the treatment of MS.6 Some of the risk factors associated 
with the development or progression of MS have been reported 
(Table 1).
At present, MS therapy is not consistently associated with any 
particular diet, probably due to lack of information on the effects 
of nutrition on the disease.5,9 However, diets and dietary 
supplements are frequently used by people with MS in the belief 
that they might improve disease outcomes in light of the 
seemingly limited effectiveness and efficacy of conventional 
treatments.3 Dietary components could, in principle, result in 
immune modulation and, thus, could be used to obtain beneficial 
outcomes in such patients.5,10 This review will focus on the 
interaction between diet and the immune system and 
inflammation in the context of MS. These effects may happen 
through direct manipulation of the inflammatory immune 
response and/or, indirectly, through modulation of the gut 
microbiota, which is also known to modulate the immune 
response.1,5,9
Interaction between diet and/or nutrients and 
the inflammatory response
Different types and amount of dietary factors can interact with 
enzymes, transcription factors and nuclear receptors of human 
cells. This may modulate the inflammatory and autoimmune 
responses in the body.10 The innate immune response is 
modulated to either the pro-inflammatory Th1/Th17 pathway, 
releasing pro-inflammatory cytokines (IL-6, IL-10), or to a down-
regulation via release of anti-inflammatory cytokines (IL-4, IL-
10).9,10
Inflammation is thought to be increased by high-energy 
Western-style diets, which are typically high in salt, animal fat, 
red meat, sugar-sweetened drinks and fried food, and low in 
fibre, as well as a lack of physical exercise. The persistence of this 
type of diet and lifestyle upregulates the metabolism of human 
cells toward biosynthetic pathways that favour the production of 
pro-inflammatory molecules and also promotion of a dysbiotic 
gut microbiota environment, with alteration of intestinal 
immunity, which is conducive to low-grade systemic 
inflammation.2,11–13
On the other hand, exercise and low-energy diets, based on the 
consumption of vegetables, fruit, legumes, fish, prebiotics and 
probiotics, act on nuclear receptors and enzymes that upregulate 
oxidative metabolism, downregulate the synthesis of pro-
inflammatory molecules, and restore or maintain a healthy 
symbiotic gut microbiota pattern.2,9
Oxidative stress, with excessive production of reactive oxygen 
species, and reduction of antioxidant defence mechanisms, has 
been implicated in the pathogenesis of MS. Therefore, much of 
the research into the role of diet and lifestyle in managing MS 
has focused on inflammation that increases the oxidative burden 
in the body.14 At present, factors linked to the inflammatory 
response that are considered to influence the course of the 
disease include Western-style high-energy diets, low availability 
and serum levels of vitamin D, postprandial inflammation 
associated with high animal fat/high sugar and refined 
carbohydrate diets and obesity (Table 2). Obesity has also been 
associated with a dysbiotic gut microbiota, alteration of intestinal 
immunity, and low-grade systemic inflammation.2,9,14
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Gut microbiome and the immune response
The human gut carries, on average, about 540 000 microbial 
genes, representing the dominant microbes in this ecosystem. 
Approximately 55% of these genes constitute the core 
metagenome (i.e. genes shared among at least 50% of 
individuals), while many other genes appear to be unique and/or 
present in less than 20% of individuals. This complex ecosystem 
is an essential part of the human organism and influences both 
our immune system and our metabolism. Therefore, it has a 
strong impact on human health.36 The gut microbiota influences 
health and nutritional status via multiple mechanisms, including 
eliminating unwanted pathogens, regulating metabolism and 
influencing the immune response.5 A mounting body of evidence 
recognises that microbial metabolites have a major influence on 
host physiology.
The composition of the intestinal microflora is highly individual 
and is influenced by many factors such as diet, physical activity, 
stress, medications and age.37−40 Dietary manipulation can 
regulate gut immunity directly through the formation of either 
T-cells that suppress immunity, or T-helper 17 cells that stimulate 
immunity.5
Moreover, dietary intake can directly modulate the microbiome 
composition and therefore function. A plant-based dietary 
intake results in a Fermicutes predominance, which ferments 
non-digestible carbohydrate and contributes to the formation of 
short-chain fatty acids (SCFA) with anti-inflammatory outcomes.2,5 
Conversely, colonic fermentation of animal-based dietary intake 
(Western diets) leads to bacteria that are more bile-tolerant.5 The 
latter results in reduced microbial diversity2 and contributes to 
low-grade inflammation.2 An increase in bile-acid production 
also results in decreased binding activity for vitamin D receptors, 
thus decreasing the effectiveness of vitamin D supplementation.2 
The most common consequence of a dysbiotic gut microbiota 
pattern is alteration of the mucosal immune system and the rise 
of inflammatory, immune, metabolic or degenerative 
diseases.4,5,41
Both disease-promoting and disease-ameliorating mechanisms 
can be induced by the gut microbiota, which interacts closely 
and mutually with the host immune system. The nature of these 
interactions seems to depend on the composition of the gut 
microbiome and the immunologic state of the host. On these 
grounds, understanding the role of gut microbiota in health and 
disease can lay the foundation to treat chronic diseases by 
modifying the composition of gut microbiota through the choice 
of a correct lifestyle, including dietary habits. Whether 
enterotypes associated with long-term diets can be reversed by 
changes in the diet remains to be determined.42
It has been argued that a nutritional intervention with anti-
inflammatory food and dietary supplements can alleviate 
possible side effects of immune-modulatory drugs and the 
symptoms of associated chronic fatigue syndrome and thus 
favour patient wellness.9 Dietary manipulation can also directly 
and indirectly affect the immune response, as will be discussed 
below.
Dietary fat and fatty acids
The relative intakes of different types of dietary polyunsaturated 
fatty acids (PUFAs) play an important role in determining the 
inflammatory state of the human body. The human body 
converts alpha linolenic acid (ALA), the omega-3 fatty acid 
mostly present in certain plant foods (flaxseeds and flaxseed oil, 
Table 1: Risk factors for the development of multiple sclerosis2,3,5,7,8
Genetics
Viral infections
Smoking
Childhood and adolescent obesity
Vitamin D deficiency/insufficiency
Vascular risk factors:
•  Obesity
•  Hyperlipidaemia
•  Hypertension
•  Heart disease
•  Diabetes mellitus
Incorrect dietary habits:
•  High-energy Western-style diet
•  High saturated fat and unrefined carbohydrate/sugar intake
•  Low dietary intake of polyunsaturated fatty acids (especially fish 
and fish oil)
Inactivity
Table 2: Pro and anti-inflammatory dietary factors
Decrease intake of pro-inflammatory dietary factors Increase intake of anti-inflammatory dietary factors
Saturated fatty acids of animal origin (keep at < 10% total energy)2,8,9 Low-calorie diets based on the assumption of vegetables, fruit, legumes, fish, 
prebiotics and probiotics8,9
Unsaturated fatty acids in the trans configuration (hydrogenated fatty acids)2,9,15 n-3 Polyunsaturated fatty acids,16,17 DHA and EPA (found in seafood and fish oil)2,18
Red meat2,19−21 Dietary fibre > 10–15 gram per day2 
Dietary salt intake above 2 300 mg/day2,8,22,23 Carotenoids (lycopene)2
Sweetened drinks, and in general high-energy diets rich in refined (low-fibre) 
carbohydrates, in addition to animal fat2,8,24−26
Vitamins D and A27
Thiol compounds such as lipoic acid, glutathione and N-acethylcysteine2,27
Oligo elements such as selenium, magnesium and zinc2,9,28−30
All polyphenols: flavonoids (quercitin, cathechins), which are present in vegeta-
bles, cereals, legumes, spices, herbs, fruits, wine, fruit juices, chocolate, tea and 
coffee31−33 and non-flavonoids (resveratrol)2,32,34
Fat-free or low-fat dairy intake8
Prebiotics (inulin, bran, oligofructose) and probiotics2,35
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canola oil, soybeans and soybean oil, pumpkin seeds)43 to the 
anti-inflammatory precursors EPA (eicosapentaenoic acid) and 
DHA (docosapentaenoic acid), the omega-3 fatty acids which are 
usually associated with fish oil. The eicosanoids derived from AA 
(arachidonic acid) generally promote inflammation, whereas 
those from EPA and DHA are less inflammatory, inactive or even 
anti-inflammatory.44 EPA and DHA compete with AA for access to 
the cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. 
High intake of long chain omega-3 EPA and DHA in the diet 
allows for the partial replacement of AA, thus reducing the 
amount available to form the metabolites that are associated 
with inflammation and chronic disorders (Figure 1).16,17
Evidence from some clinical trials on omega-3 supplementation 
point to the benefits in relapsing-remitting MS. In a systematic 
review, Farinotti et al. (2012) concluded that omega- 3 fatty acids 
seem to have no major effect on disease progression of MS, but 
tend to reduce the frequency of relapses over two years.45 In 
2013, based on its anti-inflammatory and neuroprotective 
action, daily oral supplementation with 4 g of fish oil was found 
to be highly effective in reducing the levels of pro-inflammatory 
cytokines and nitric oxide in patients with relapsing-remitting 
MS (RRMS).14 In another randomised controlled clinical trial, a 
nutraceutical mixture of omega-3 and omega-6 fatty acids with 
vitamins was found to significantly reduce the relapse rate and 
the disability progression in patients with RRMS.43 Secondary 
analysis of data from the Nurses’ Health Studies I and II found a 
higher baseline PUFA intake to be associated with a lower risk for 
MS. This was specific for an inverse association between intake of 
ALA and risk for MS.7
Pantzaris et al. (2013) and Farinotti et al. (2012) concluded that 
the available data are insufficient to assess real benefit or harm 
from omega-3 supplementation, mostly because of the uncertain 
quality of the trials.43,45 This was recently confirmed by the 2017 
European Society for Clinical Nutrition and Metabolism (ESPEN) 
evidence- and consensus-based guidelines for neurological 
states, which state that there is insufficient evidence to 
recommend omega-3 supplements to MS patients.46 It is, 
however, interesting to note that DHA is present in high 
concentrations in the brain and its levels decrease in patients 
with MS.7,9
Vitamin D
Epidemiological studies have highlighted possible links between 
vitamin D insufficiency and a wide range of human diseases, 
including MS.2,4,8,47,48 Based on these studies, vitamin D deficiency 
seems to impact on both the onset and progression of MS.4 It is 
believed that these effects are mediated via the immune-
modulatory (anti-inflammatory) role of vitamin D4,8,49 and/or via 
the ability of vitamin D to transcript certain genes associated 
with MS.4 The clinical importance of this with regard to vitamin D 
insufficiency and immune-related diseases is discussed in more 
detail elsewhere.49 The anti-inflammatory properties of vitamin D 
require the binding of calcitriol to the vitamin D receptor (VDR) 
of calcitriol [1,25-(OH)2D3]. Once it is formed, the complex VDR-D 
binds to the Retonoid X receptor (RXR) activated by its ligand 
retinoic acid (RA), the main metabolite of vitamin A. The 
heterodimer complex RXR–RA/VDR-D controls the expression of 
several genes involved in inflammatory and autoimmune 
processes in chronic diseases by inhibiting the pro-inflammatory 
transcription factor NF-κB and downregulating the synthesis of 
inflammatory molecules. For vitamin D supplementation to exert 
an adequate anti-inflammatory action, it should be administered 
together with vitamin A.2
Vitamin D also controls tight junctions to maintain mucosal 
integrity. Vitamin D deficiency can thus result in mucosal 
permeability and contribute to gut dysbiosis.2
Figure 1: Metabolism of omega-6 and omega-3 polyunsaturated fatty acids (figure used with permission. COX-2: cyclooxygenase, LOXs: lipoxygenase, 
TXA2: thromboxane A2 (platelet aggregator, vasoconstrictor), PGI2: prostaglandin I2 (vasodilator, anti-aggregator), PGE2: prostaglandin E2 (immuno-
suppressor) 44
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supplementation (25 000 IU/d retinyl palmitate for 6 month and 
10000 IU/d for the next 6 months) on the clinical status, relapse 
rate and brain lesions in patients with MS. Vitamin A 
supplementation improved the MS functional composite score 
(measures the progression of disability as indicated by cognitive, 
lower and upper limb function), expanded disability status scale 
(determines lower limb function dominantly), relapse rate and 
brain lesions.61
Lifestyle factors
Lifestyle factors such as smoking, alcohol use and physical 
activity may exacerbate or ameliorate MS symptoms by 
modulating the inflammatory status of the disease.2,9
Although controversial,2 both active and passive cigarette 
smoking is associated with the development of MS in a dose-
dependent manner. Smoking is also associated with a faster 
deterioration and progression of disability in those with MS.4,8 
Smoking has been shown to have a direct and indirect (via gut 
microbiome) pro-inflammatory effect.2
Studies of the impact of alcohol consumption on MS have 
produced inconsistent results. However, recent studies do not 
appear to support alcohol (beer, wine or liquor) consumption 
being associated with MS risk.2,62,63
Conversely, the role of physical activity in MS is clearer. Activity 
results in decreased leptin levels.2 Leptin is associated with fewer 
regulatory T-cells and thus with a more pro-inflammatory 
state.3,87 Through the anti-inflammatory effects of reduced leptin 
levels, the quality of life is greatly improved.2,64 Less fatigue and a 
The risk for MS is increased in individuals exposed to vitamin D 
deficiency during adolescence and early adulthood. Deficiency 
during pregnancy has also been linked to increased risk for MS in 
the offspring.4
In individuals with established MS, vitamin D deficiency was also 
associated with increased disease progression.8 Uncertainty still 
exists though about the optimal serum level of 25(OH)D in 
individuals with MS to ensure best outcomes. One such study 
reported a target of 100 nmol/l (40 ng/ml).4
The role of routine use of vitamin D in MS patients, their first-
degree relatives and people at risk of MS is still being debated 
and varies between different countries and even between 
practising neurologists working in the same area. Nevertheless, 
accumulating evidence from experimental, epidemiologic and 
clinical studies supports the potential link between poor vitamin 
D status and the risk of developing MS, as well as adverse disease 
course.9,47
Clinical outcomes of trials with vitamin D supplementation in MS 
patients are less consistent.50,51 Patients with MS have low levels 
of vitamin D,47 but this is true for other chronic inflammatory 
diseases as well.52,53 Studies mostly assessed the mechanism of 
the protective role of vitamin D in experimental autoimmune 
encephalomyelitis (EAE). The proposed underlying mechanisms 
for this relationship are inducing inflammatory cell apoptosis54 
i.e. CD4 T-cells,55 suppressing immune cell infiltration into the 
CNS, i.e. CD 11b monocytes, decreasing inducible nitric oxide 
synthase,54,55 as well as inhibiting pro-inflammatory cytokine 
secretion including IL-12 and IFN-γ.56,57
Recommendations for vitamin D supplementation in MS have 
been put forward by many, including consensus guidelines that 
answered some important questions on this topic according to 
the available evidence or experts’ opinions, which was published 
by Jahromi et al. (2016).51 These recommendations are 
summarised in Table 3. Although there is insufficient evidence to 
implement these guidelines as universal recommendations to 
reduce the risk for MS development, the recommendations are 
aimed at individuals with a family history of MS, those with 
clinically isolated syndrome (CIS) (patients who have experienced 
a solitary clinical event of demyelination, but not fulfilled the 
diagnostic criteria for MS or any other related disease)51 and 
those living in areas where vitamin D deficiency is prevalent.4
The latest 2017 ESPEN guidelines on best medical nutrition 
therapy in patients with neurological diseases concludes that 
there is insufficient evidence to recommend vitamin D therapy in 
MS patients.46 According to ESPEN, there is no clinical evidence 
on the effects of either vitamin D compared with placebo or 
high-dose vitamin D compared with low-dose on the relapse 
rate of patients with MS.46 The studies that evaluate the effect of 
vitamin D are prone to many sources of bias (selection bias due 
to diet or sun exposure, reverse causation due to the disease, and 
effect of the skin type or genetic factors).
Vitamin A
Studies have shown that active vitamin A derivatives suppress 
the formation of pathogenic T cells in MS patients. Over the last 
two decades, it has become clear that vitamin A also has 
important roles in immune functioning, both in immunological 
tolerance and in adaptive immune responses.59,60 Recently 
Bitarafan et al. (2015) conducted a randomised placebo-
controlled clinical trial to investigate the effect of Vitamin A 
Table 3: Proposed management guidelines for Vitamin D and multiple 
sclerosis2,4,5,8,51–58
Supplementation seems to be reasonable for all MS and CIS 
patients, especially after the first demyelinating attack51
Aim for an optimal serum level of 25(OH)D ranging between 20 and 30 ng/ml;8 
30–60 ng/ml2,4 in all MS patients after diagnosis and the first demyelinating 
attack
Normality is currently between 30 and 100 ng/ml (75 and 250 nmol/l). Less 
than 10 ng/ml is considered as deficiency and a range between 11 and 30 ng/
ml is considered as insufficiency
In patients with vitamin D insufficiency or deficiency, a large initial replacing 
dose (e.g. 50 000 IU vitamin D per week for 8–12 weeks) is recommended8
Vitamin D3 (cholecalciferol) is preferred above vitamin D2 (ergocalciferol) due 
to it being more biologically active, having a more stable shelf-life and a more 
effective ability to raise blood levels8
The serum vitamin D, and calcium level, as well as patients’ compliance, should 
be monitored after the initial phase of 8–12 weeks8,51
Maintenance treatment of 1 500–2 000 IU daily or equivalent intermittent 
(weekly, biweekly or monthly) dose is recommended thereafter. This mainte-
nance dose varies according to different authors from 2 000–4 000 IU daily4 
to 2 000–5 000 IU daily in areas of severe vitamin D deficiency,8 with others 
recommending 3 500–5 000 IU daily.2 The maintenance dose can also be 
adapted according to serum levels with 1 000 IU recommended daily if serum 
levels between 20 and 30 ng/ml and 2 000 IU daily if below 20 ng/ml8
A routine check of serum vitamin D level at least twice a year is recommended, 
especially at the beginning of spring and autumn51
Serum vitamin D evaluation for first-degree relatives of MS patients at high 
risk age and supplementation in case of insufficiency (25(OH)D less than 
40 ng/ml) is recommended51
Correction of vitamin D deficiency and insufficiency before pregnancy, as well 
as a daily dose of 1 500–2 000 IU or equivalent biweekly intake in 2nd and 
3rd trimesters and stopping supplementation if 25(OH)D serum level exceeds 
100 ng/ml, is recommended51
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effects of probiotic intake on disability, mental health and 
metabolic condition in subjects with MS.66 The probiotic 
contained Lactobacillus acidophilus, Lactobacillus casei, 
Bifidobacterium bifidum and Lactobacillus fermentum (each 2 x 
109  CFU/g). The study demonstrated that the use of probiotic 
capsules for 12 weeks among subjects with MS had favourable 
effects on the expanded disability status scale (EDSS), as well as 
on parameters of mental health, inflammatory factors, markers 
of insulin resistance, HDL-, total-/HDL-cholesterol and 
malondialdehyde (MDA), a lipid peroxidation marker, levels.66
Highly selective experimental strategies will be needed to 
manipulate specific subsets or even single strains of bacteria as a 
therapeutic approach for MS. Rothhammer and Quintana 
(2016)67 demonstrated that tryptophanase-positive bacteria, 
such as Lactobacillus reuteri, generate indole from dietary 
tryptophan, which is metaboliaed by the host to indole-3-sulfate 
(I3S), indole-3-propionic acid (I3PA) and indole-3- aldehyde (I3A). 
Indole, I3S, I3PA and I3A cross the blood–brain barrier and 
suppress pro-inflammatory activities by activating aryl 
hydrocarbon receptor (AHR) in astrocytes (dominant glial cells in 
the brain). Lack of dietary tryptophan or deficiency of AHR in 
astrocytes caused a failure to recover during chronic stages of 
EAE. Patients with MS seem to harbour deficits in the generation, 
uptake or stability of these anti-inflammatory metabolites, 
resulting in a decrease in their levels and in AHR-dependent 
immune regulation.68,69
Another more drastic therapeutic approach proposed to restore 
gut eubiosis, and downregulate inflammation, by faecal 
microbiota transplantation, a practice that is neither t-tested nor 
used or recommended in MS.69
Conclusion: current best dietary advice for MS
Insufficient high-quality evidence exists in the scientific literature 
to inform official clinical recommendations.2,70 However, based 
on the available data that inflammation plays a role in MS 
treatment, the anti-inflammatory dietary and lifestyle approach 
is currently considered the best and safest approach.
Lifestyle modifications (weight management, increased physical 
exercise and abstinence from smoking) are some of the 
important interventions that can be implemented to decrease 
the onset and/or slow the progression of MS.4,8 The current 
recommendation for MS is an anti-inflammatory diet lower in 
saturated fats (fatty meat, fried food, confectionery, full-cream 
dairy products) and high in monounsaturated fats (canola oil, 
olives and olive oil, nuts, seeds, avocados) and polyunsaturated 
fats (flaxseed oil, fish and fish oil).8,71,72 Patients who do not eat 
oily fish at least three times a week can increase their intake of 
omega-3 fatty acids with supplements. Fish oil is the best source 
of EPA and DHA.73
Patients who are overweight with a high compliance should 
follow a low-energy diet (1 600–1 800 kcal) based on vegetables, 
whole cereals, legumes, fruit and fish, which may decelerate the 
progression of the disease and improve the wellness of MS 
patients. Such dietary therapy could also include 
recommendations on improving the n-3 PUFA, probiotic and 
vitamins A and D intake of these patients. Probiotics, such as 
Lactococcus lactis, Bifidobacterium lactis, Clostridium butyricum, 
Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium 
bifidum and Lactobacillus fermentum, can improve the intestinal 
microbial balance.9,53
slower progression of debilitating symptoms have also been 
reported in patients with MS who partake in exercise.2
The physical activity recommendations for individuals for MS are 
20–60-minute sessions of moderate-intensity aerobic exercises 
at least 3–4  days per week, as well as 10–15 minute strength 
training sessions 2–3  days per week. Daily stretching exercises 
for 10–15 minutes are also recommended.8
Obesity and weight management
A two- to threefold increased risk for MS has been reported in 
overweight individuals. These associations have been 
documented for overweight/obese children and adolescents4,5 
and were more pronounced in females.3−5 Obesity is known to be 
associated with persistent low-grade inflammation.3−5, 8 It is also 
inversely associated with a decrease in vitamin D levels5,46 and 
increased leptin levels.3,4,9
Gut microbiota have also been reported to be also influenced by 
body mass index (BMI). With a higher BMI, gut microbiome 
diversity decreases and the latter has been linked to increased 
risk for developing MS.5 Low diversity is associated with insulin 
resistance, hyperlipidaemia and increased inflammatory 
markers.5
High-energy, Western-type diets with high intake of salt, 
saturated animal fat, fried food and sugar-sweetened drinks may 
lead to the onset of postprandial inflammation and systemic 
low-grade inflammation. Conversely, with energy restriction, 
insulin release is decreased. Increased insulin levels result in an 
increased production of AA, which has pro-inflammatory effects 
(see Figure 1).2,9
Diet quality and MS
Better quality of life (QoL) and lower risk of debilitating disabilities 
are associated with an improved dietary quality (higher intake of 
fruit, vegetables and fish).5 The association between diet quality 
and disability status was determined in 6 989 individuals with 
diagnosed MS. Those with diet quality scores in the highest 
quintile had lower levels of disability and lower depression 
scores. The odds of reporting severe fatigue, depression, pain or 
cognitive impairment were lower for those individuals with 
composite healthy lifestyle factors.65
Riccio et al. (2016) 53 showed that nutritional interventions are 
well accepted by people with MS and may ameliorate their 
physical and inflammatory status. A dietary regimen mainly 
based on principles of Mediterranean diet, with or without 
administration of dietary supplements, determined an increase 
of the ratio n-3/n-6 PUFA serum concentration thus supporting 
the general trend towards an amelioration of inflammatory 
status. Patients with primary progressive MS (characterised by 
worsening neurologic function and accumulation of disability 
from the onset of symptoms) were more responsive to nutritional 
intervention with fish oil and lipoic acid.9
As various studies report different levels of efficacy, it is difficult 
to make recommendations based on specific nutrients of food 
groups. Overall, healthy eating guidelines are therefore currently 
recommended.5
Probiotic supplements and MS
In a recently published randomised double-blind placebo-
controlled clinical trial, Kouchaki et al. (2016) evaluated the 
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